It is well known that patients with glucokinase inactive mutations [glucokinase–maturity-onset diabetes of the young (GCK-MODY) or MODY2] rarely develop diabetic complications, especially cardiovascular diseases (CVDs), and typically do not require treatments (1). The gene discussed is GCK; the disease is maturity-onset diabetes of the young.